ABSTRACT
Microglial responses to cerebral ischemia are tightly regulated by inhibitory pathways that limit excessive post‐stroke inflammation. Transmembrane protein 119 (Tmem119) has emerged as an important regulator of microglial activation and neuroinflammatory signaling. We investigated the role of microglial Tmem119 during acute ischemic stroke using primary microglia and a young adult mouse model. Primary microglia were transfected with Tmem119‐siRNA and subjected to oxygen–glucose deprivation (OGD) alone or combined with lipopolysaccharide (LPS) stimulation. In vivo, young adult male mice received stereotaxic injection of lenti‐Tmem119 or lenti‐GFP for 4 weeks before 60 min of transient middle cerebral artery occlusion (MCAO). Tmem119 expression and inflammatory responses were assessed by qPCR, Western blotting, and ELISA at 1 and 3 days after stroke. Infarct volume and neurobehavioral outcomes were also evaluated. Tmem119 silencing significantly increased IRAK4, IRF5, and CD68 mRNA expression in primary microglia. Ischemic injury reduced microglial Tmem119 protein expression and increased IRAK4 signaling in vivo. In contrast, lenti‐Tmem119 treatment before MCAO decreased phosphorylated IRAK4 protein expression and increased IL‐10 levels in both plasma and ischemic brain tissue compared with lenti‐GFP controls. Tmem119 overexpression also significantly reduced infarct volume and improved neurobehavioral outcomes. These findings demonstrate that microglial Tmem119 exerts a protective anti‐inflammatory role during the acute phase of ischemic stroke by suppressing IRAK4‐mediated inflammatory signaling and enhancing IL‐10 production. Collectively, Tmem119 limits microglial activation, reduces ischemic brain injury, and improves functional recovery, identifying Tmem119 as a promising therapeutic target for ischemic stroke.
Keywords: inflammation, IRAK4, ischemic stroke, microglia, Tmem119
Microglial Tmem119 knockdown increases inflammatory signaling following oxygen–glucose deprivation (OGD).
Tmem119 overexpression attenuates IRAK4‐mediated inflammation, enhances IL‐10 production, reduces ischemic brain injury, and improves neurological outcomes after stroke.

1. Introduction
Ischemic stroke‐induced inflammation is tightly regulated by microglial cell‐surface regulatory proteins (Patel et al. 2013; Wang et al. 2022). Dysregulation of any of these membrane regulatory proteins can trigger maladaptive immune responses, characterized by excessive production of pro‐inflammatory mediators or insufficient release of anti‐inflammatory factors (Ajoolabady et al. 2025; Zhao et al. 2022).
Transmembrane protein 119 (Tmem119), a microglial associated marker, has recently received considerable attention as a biomarker in multiple neurological disorders, including stroke (Wang et al. 2022; Young et al. 2021), traumatic brain injury (Mercurio et al. 2022), multiple sclerosis (Vankriekelsvenne et al. 2022), and Alzheimer's disease (Liu et al. 2025). Despite these findings, its role in cerebral ischemia remains poorly understood.
Tmem119 is a type‐1A membrane protein expressed specifically by microglia in the brain (Bennett et al. 2016; Mercurio et al. 2022; Satoh et al. 2016). Evidence suggests that Tmem119 contributes to microglial activation (Bennett et al. 2016; Kiani Shabestari et al. 2022; Li et al. 2018; Satoh et al. 2016). Tmem119 has also been proposed to function as a homeostatic microglial gene (Kiani Shabestari et al. 2022), helping maintain microglia in a resting state. However, under pathological conditions, Tmem119 expression is reduced (Bennett et al. 2016; Vankriekelsvenne et al. 2022). For example, in a mouse model of traumatic brain injury (TBI), microglial Tmem119 expression decreased at 4 and 7 days post injury (Mercurio et al. 2022). This reduction is associated with increased expression of the inflammatory marker CD11b (Mercurio et al. 2022; Vankriekelsvenne et al. 2022), suggesting that increased expression of Tmem119 counteracts pro‐inflammatory signaling.
Despite these observations, the function of Tmem119 signaling in ischemic stroke has not been well characterized. Developing strategies to modulate microglial cell‐surface membrane proteins such as Tmem119 before and after ischemic stroke remains a major challenge.
IRAK4 (interleukin‐1 receptor‐associated kinase 4) is a key downstream effector of Toll‐like receptor 4 (TLR4) and plays an important role in regulating innate immune responses by mediating the TLR4 signaling cascade (Ngwa, Mamun, et al. 2021; Suzuki et al. 2002). In addition to these reports, systemic inflammation studies on macrophage activation have suggested IRAK‐4 (interleukin‐1 receptor‐associated kinase 4) and the adaptor protein MyD88 (Myeloid differentiation primary response 88) are crucial in phosphorylation of transcription factors (De Nardo et al. 2018; Ngwa, Mamun, et al. 2021; Pereira and Gazzinelli 2023). We hypothesize that microglial Tmem119 inhibits IRAK4, thereby promoting anti‐inflammatory and reducing pro‐inflammatory microglial signaling after ischemic stroke. We predict that interruption of the Tmem119‐IRAK4 inhibitory axis will worsen stroke outcomes.
Ischemic stroke treatment remains challenging, as no effective therapies directly targeting post‐stroke inflammation have been approved (Lambertsen et al. 2019; Paul and Candelario‐Jalil 2021; Yang et al. 2021), and the role of microglial Tmem119 signaling in ischemic stroke is unclear. To investigate whether Tmem119 inhibits IRAK4 and its downstream inflammatory consequences after stroke: (i) we silenced microglial‐Tmem119 in primary microglial from neonatal C57BL/6N wild‐type (WT) mice using Tmem119‐siRNA, and (ii) overexpressed Tmem119 in C57BL/6N WT mice (4–8 months old) using a lentiviral vector expressing Tmem119 under the CX3CR1 promoter. Control primary microglial or mice received a matched scrambled siRNA or lentivirus expressing green fluorescent protein (GFP). Our findings demonstrate that microglial Tmem119 plays an anti‐inflammatory role in regulating immune responses and outcomes to ischemic stroke in male mice, possibly through inhibition of IRAK4.
2. Materials and Methods
2.1. Animal Models
C57BL/6N wild‐type (WT) mice were used in this study. Male and female mice were obtained from National Institutes of Aging (NIA) or purchased from The Jackson Laboratory. Prior to experimentation, male mice weighed 25–35 g and female mice weighed 23–30 g. Mice were group‐housed under pathogen‐free conditions with a 12‐to‐12‐h day‐night cycle and had access to food and water ad libitum. Mice were 4–8 months old at the time of experimentation and were randomly allocated to the experimental groups for lentiviral transduction and subsequently middle cerebral artery occlusion (MCAO) or sham surgery. All studies were conducted in accordance with NIH guidelines for the care and use of laboratory animals and approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Texas Health Science Center at Houston McGovern Medical School.
Investigators were blinded to group allocation during surgery, outcome assessment, image analysis, and statistical analysis. Experimental groups included lenti‐GFP and lenti‐Tmem119, with MCAO/sham‐operated groups as applicable. Animals were monitored throughout the experimental period for body weight and assessment of general health, neurological status, and postoperative recovery. A loss of > 20% baseline body weight following lentiviral administration or MCAO was predefined as a humane endpoint based on the approved protocol. Animals reaching this endpoint or exhibiting other signs of severe distress were humanely euthanized before completion of the experimental procedures were documented, and exclusion from subsequent analyses were reported where applicable. Sample sizes for each experimental group are provided in the corresponding figure legend and/or result section.
2.2. Primary Microglia Culture, siRNA Treatment, Oxygen–Glucose Deprivation, Cell Viability Assay
We have previously cultured primary microglia as in (Ngwa, Qi, et al. 2021; Ngwa, Mamun, et al. 2021; Qi et al. 2021; Tabor et al. 2021), and used the same procedure with modification. Briefly, primary microglia were obtained from postnatal day 0–4 C57BL/6N male and female mice using the neural tissue dissociation kit P_130092628 (Miltenyi Biotech). The cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) with phenol red and supplemented with 10% FBS, 1% P/S, and 6% L929‐conditioned medium at day 3–5 (Qi et al. 2021). After 12–15 days, flasks were shaken to collect loosely attached, mature microglia.
Transmembrane 119 (Tmem119) is specifically expressed by microglia in the brain (Bennett et al. 2016; Mercurio et al. 2022). To confirm/validate our primary microglial cells we perform immunocytochemistry (ICC) as in (Al Mamun et al. 2020; Qi et al. 2021). We used rabbit anti Tmem119_27,585–1AP, 1:200 (Proteintech, USA) primary antibody and Donkey anti‐rabbit Alexa Fluor 488_A‐21,206 1:400 (Thermo Scientific, USA). Images were captured in a Confocal Microscope, and fluorescence intensities were quantified by ImageJ.
For cell treatment and oxygen–glucose deprivation (OGD), primary microglia derived from male and female mice were cultured and treated separately. Cells were seeded in 12‐welled plates (200,000–400,000 cells per well) and allowed to ramify for 2 days in DMEM_31053028 (Thermo Scientific, USA), and supplemented as in (Qi et al. 2021). Tmem119‐siRNA_sc‐154,354 or scrambled‐siRNA_sc‐37,007 (Santa Cruz Biotechnology, USA) were suspended in Opti‐MEM containing lipofectamine RNAiMAX buffer at a treatment concentration of 100 nM. The suspended Tmem119‐siRNA or scrambled‐siRNA were then added to the cells in the 12‐welled plate for 4 h. Oxygen–glucose deprivation (OGD) was carried out as in (Ngwa, Mamun, et al. 2021). Briefly, the culture medium from siRNA‐treated or untreated cells was replaced with glucose‐free DMEM_A1443001 (Thermo Fisher Scientific), and then a sealed chamber (sterile) was used to place the plates (opened), followed by oxygen expiration inside the chamber for 10 min via flowing in 95% N2 and 5% CO2 mixture persistently. The chamber was transferred into a 37°C incubator after clamping the inlet and outlet (from air circulation) for 4 h. During OGD, O2 levels dropped to < 2% after 2 h, and to < 1% at 4 h, as shown by a change in color of BD_271051 anaerobic indicator strips (inserted both inside and outside of the chamber) from blue (aerobic) to white (anaerobic) coloration. After 4 h OGD, the medium in a well was replaced with DMEM_31053028 without LPS or containing LPS (100 ng/mL) and allowed in a Forma Steri‐Cycle CO2 incubator at 37°C, 95% humidity and 5% CO2, for 24 h. Cell culture supernatants were collected for cytokine assay, meanwhile microglia were used for morphology, cell viability, and gene/protein expression studies.
For cell viability assay, we used CellTiter 96 AQueous Non‐Radioactive Cell Proliferation Assay kit_G5421 as in (Tanifum et al. 2018) with modifications. Briefly, 50,000 microglial cells/well plated in 96‐well tissue culture plates were exposed to OGD for 4 h and then stimulated with LPS (100 ng/mL in DMEM_31053028) or left unstimulated (OGD‐only) for 24 h. After treatment, the cell culture medium inside a well was replaced with 50 μL of MTS/PMS reagent and incubated for 5 h in 95% oxygen, 5% CO2, and at 37°C. Absorbance readings were subsequently measured at 450 nm in EnSpire Multimode Plate Reader. All control experiments were performed under identical conditions. Microglia exposed to LPS‐only, OGD alone (OGD only), or OGD + LPS‐only did not receive siRNA treatment. Normoxia microglial cells were used as negative controls for OGD experiments; meanwhile, scrambled siRNA was used as a negative control for all Tmem119‐siRNA experiments. To validate the reproducibility and the knockdown, an independent Tmem119‐siRNA (SR408041) and corresponding scrambled control siRNA (SR30004) from ORIGENE (USA) were also tested. Comparable efficiency and experimental outcomes were observed with both siRNA reagents.
2.3. Stereotaxic Injection of Lenti‐GFP or Lenti‐Tmem119
Custom lentiviral vector encoding Tmem119 under the control of the CX3CR1 promoter, designed for microglia‐specific expression, were used (Genecopoeia, MD, USA). Lenti‐GFP or lenti‐Tmem119 was delivered using a stereotaxic apparatus following previously established protocols (A. Al Mamun et al. 2020; Bertot et al. 2019; Rimmerman et al. 2017). Briefly, a total of 50,000 TU (1 μL) of lentivirus was delivered per injection site. For the four‐point injection paradigm, lentivirus was administered at a rate of 0.5 μL/min using a 26‐gauge needle attached to a 5‐μL Hamilton syringe (Removable Needle, RN; PN: 87930). Prior to viral injection, Bupivacaine (0.25%) was locally administered at the surgical site for analgesia. Lentivirus was injected bilaterally into the cortex/striatum with two injection sites per hemisphere. The stereotaxic coordinates were 0.5 mm anterior/posterior to bregma, 2.0 or 3.0 mm lateral, and 1.0 or 2.8 mm ventral. Following each injection, the needle was left in place briefly and then slowly withdrawn to minimize viral reflux. The incision area was subsequently closed with 6–0 vicryl (Ethicon) sutures. After surgery, mouse was removed from the stereotaxic frame and monitored throughout recovery until was fully ambulatory. Mice were allowed for 4 weeks post‐injection to achieve robust transgene expression and were subsequently either euthanized for validation studies or subjected to middle cerebral artery occlusion (MCAO) surgery. Mouse and body weight were monitored following lentivirus administration and recorded every 10 days for a total duration of 47 days to assess potential toxic effects associated with lentiviral treatment. The experimental timeline for this in vivo study is presented in Supplementary Figure 7.
2.4. Ischemic Stroke Model
Cerebral ischemia was induced in mice by transient middle cerebral artery occlusion (MCAO) and under isoflurane anesthesia as previously described (Abdullah Al Mamun et al. 2020; Liu et al. 2009; Ngwa et al. 2026; Qi et al. 2023). Briefly, a midline ventral neck incision was made, and unilateral MCAO was performed by inserting a 6–0 silicone‐coated suture into the right internal carotid artery 6 mm from the internal carotid/pterygopalatine artery bifurcation via an external carotid artery stump. Reperfusion was performed by withdrawing the suture 60 min after the occlusion. Rectal temperature was maintained at 36.5°C ± 0.5°C during surgery with an automated TC‐1000 temperature‐control feedback system (CWE Inc., Ardmore, PA, USA). All mice were monitored daily and then sacrificed at 3 days post‐stroke for analysis of stroke outcomes and microglia responses, and lesion size.
2.5. Enzyme‐Linked Immunosorbent Assay (ELISA)
We used the same procedure as in (Ngwa et al. 2022; Qi et al. 2021). Blood samples were obtained by cardiac puncture with EDTA‐soaked syringed‐needles and then centrifuged at 15,000 RPM for 20 min, and at 4°C. Brain tissue in non‐pyrogenic 5 mL polystyrene round‐bottom tubes (Ref # 352235, Corning USA) was homogenized using glass pistons in complete NP40 buffer and also centrifuged at 15,000 RPM for 20 min, and at 4°C. After centrifugation, the supernatant was collected and assayed in Nunc MaxiSorp ELISA plates_423501 and using ELISA MAX Deluxe kits. For brain cytokine assays, we used 5–10 μg total protein dispersed in 100 μL final volume.
2.6. Western Blot, Immunocytochemistry, Immunohistochemistry and Cresyl Violet Staining
We have previously performed Western blotting and immunocytochemistry (ICC) in cell lines, primary cells, or brain homogenates as in (Ngwa, Mamun, et al. 2021; Qi et al. 2021), and used the same procedure with modifications. Briefly we used 4%–15% Mini‐PROTEAN TGX Gels_5671085, 4,561,086, 5,671,084, or 4,561,084 (BioRad, Hercules, CA) depending on the protein volume and the number of assays, and 15–30 μg total protein was loaded into each well of gel. Specific primary antibodies including anti‐Tmem119 (Proteintech_66948–1‐Ig: 1:4000), anti‐IRAK4 (Cell Signaling Technology_4363, 1:1000), anti‐phospho‐IRAK4 (Cell Signaling Technology_11927, 1:1000), and anti‐β actin as loading control (Cell Signaling Technology_4970, 1:1000) were used.
For immunocytochemistry, paraformaldehyde‐fixed primary microglial cells were used; meanwhile, for immunohistochemistry, we used 30 μm brain slices. To stain brain tissue on a glass slide, tissue was blocked in 0.3% Triton X‐100, 1% bovine serum albumin (BSA), and 5% donkey serum for 2 h at room temperature. The tissue was then incubated overnight at 4°C with the primary rabbit anti‐Tmem119 (cat# 27585–1‐AP, 1:400; Proteintech). After 1 h of incubation at room temperature, tissue was washed in 1× PBS. Tissue was then incubated with donkey anti‐rabbit Alexa Fluor 594 (1:400, Thermo Fisher Scientific) for 1 h at room temperature. Nuclei were counterstained with DAPI (Thermo Fisher Scientific). Fluorescence images were acquired from three random 20× fields per animal and within similar cortical areas or acquired from random 10× fields of whole brain sections per animal.
Brain tissue (30 μm), cut using a freezing microtome and processed on positive charged glass slides, was used for Cresyl Violet (CV) staining. Eight slices of brain section, corresponding to the whole mouse brain, were stained with CV as in (Al Mamun et al. 2020; Li et al. 2004; Ngwa et al. 2024; Ngwa et al. 2022).
2.7. RNA Extraction and qRT‐PCR
Total RNA was extracted from normoxia, OGD, Tmem119‐siRNA or scrambled‐siRNA treated, Tmem119‐siRNA or scrambled‐siRNA+OGD + LPS stimulated microglia as in (Qi et al. 2021; Tabor et al. 2021). The method used for quantitative Real Time PCR (qPCR) was: 95°C (3.00 min), 95°C (10 s), and 60°C (30 s), and 40 cycles. The following gene primers from Integrated DNA Technologies (IDT), were used for q‐PCR: Tmem119 F_GTG TCT AAC AGG CCC CAG AA, Tmem119 R_AGC CAC GTG GTA TCA AGG AG; CD68 F_ACT TCG GGC CAT GTT TCT CT, CD68 R_GCT GGT AGG TTG ATT GTC GT; IRAK4 F_CCA TCG TGG CGG TGA AG, IRAK4 R_GTG CTG ACA CGT TGC CAT TAC T; CD206 F_CAA GGA AGG TTG GCA TTT GT, CD206 R_CCT TTC AGT CCT TTG CAA GC; IRF5 F_CCT CAG CCG TAC AAG ATC TAC GA, IRF5 R_GTA GCA TTC TCT GGA GCT CTT CCT, IL‐1β F_GTT TCT GCT TTC ACC ACT CCA, IL‐1β R_GAG TCC AAT TTA CTC CAG GTC AG; IL‐10 F_GCG CTG TCA TCG ATT TCT CC, IL‐10 R_TGG CCT TGT AGA CAC CTT GG; and the housekeeping gene GAPDH F_GTG TTC CTA CCC CCA ATG TGT, GAPDH R_ ATT GTC ATA CCA GGA AAT GAG CTT. The results were reported as normalized fold changes in mRNA, which were calculated via the ΔΔCt method using the threshold cycle (Ct) value for respective gene of interest.
2.8. Behavioral Testing
All behavioral tests were performed by a blinded investigator, and included (i) neurologic deficit scores (NDS) (Al Mamun et al. 2020; Ngwa et al. 2022); (ii) Open field (Kraeuter et al. 2019; Qi et al. 2023); (iii) Grip strength (Cabe et al. 1978; Meyer et al. 1979; Smith et al. 1995); (iv) Alternation or Y‐maze Test: (Prieur and Jadavji 2019; Qi et al. 2023). The alternation test consists of a single 5 min trial. Spontaneous Alternation (%) is defined as consecutive entries in 3 different arms (arm A, B, C), divided by the number of total alternations (total arm entries minus 2) (Hsiao et al. 1995). Mice with less than 8 arm entries during the 5‐min trial were excluded from the analysis. An entry occurs when all four limbs are within the arm. All the arms were cleaned between each trial.
2.9. Isolation of Microglia by MojoSort
Microglia used for qPCR and Western blot were isolated from brain tissue homogenate as in (Ngwa et al. 2025), with modification. Briefly, brain tissue was homogenized in a combined enzyme mix prepared from the Neural Dissociation Kit (P) (cat #130–092‐628, Miltenyi Biotec). The homogenate was washed with cold PB buffer (10 mL) and centrifuged at 300 × g for 5 min at 4°C. The resulting pellet was resuspended in 1 mL of cold PB buffer and transferred to a 15 mL Falcon conical polypropylene centrifuge tube (cat #352196). PE‐conjugated Tmem119 monoclonal antibody (cat #12–6119‐82, Invitrogen) was added at 5 μg (25 μL) per homogenate (equivalent to one brain hemisphere). The suspension was gently mixed and incubated on ice for 15 min. MojoSort mouse anti‐PE Nanobeads (Lin et al. 2021; Ma et al. 2022) (cat #480080, BioLegend; 27 μL) were then added. The mixture was gently pipetted up and down to ensure uniform distribution and incubated on ice for an additional 20 min. Following incubation, 14 mL of cold PB buffer was added to dilute the content of the tube. The content of the tube was mixed by gentle inversion (15 times). The tube was then placed on a magnetic rack (cat #1045, Sergi Lab Supplies) at 4°C for 20 min with gentle shaking. The supernatant was carefully decanted without removing the tube from the magnetic rack. The magnetic bead‐bound cells were washed twice with cold PB buffer to remove cell debris and dead tissue. The tube was then removed from the magnet and Tmem119+ microglia (Tmem119+ microglia/PE‐antibody/anti‐PE Nanobead fraction) were resuspended in 1 mL of cold PB buffer and transferred to a 1.7 mL microcentrifuge tube. Cells were counted using a hemocytometer and centrifuged at 500 × g for 5 min at 4°C. The supernatant was removed, and the cell pellet was either used immediately or stored at −80°C for later use.
2.10. Statistical Analysis
The sample size for the MCAO experiments was determined based on our previous experience with the MCAO model, published studies using similar experimental paradigms, and institutional experience regarding the variability of infarct volume and behavioral outcomes after experimental stroke. No formal priori power calculation was performed. Depending on the experimental design, male‐ and female‐derived microglia were either analyzed separately by sex or pooled for treatment‐versus‐control analyses. Data from individual experiments were presented as mean ± SD, and assessed by Student's t‐test, One‐way ANOVA or 2‐way ANOVA with Tukey post hoc test for multiple comparisons using GraphPad Prism Software 10.1.2 (324).
p < 0.05 was considered statistically significant. Investigators were blinded to mouse strains for stroke surgery, behavioral testing, infarct, and inflammation analysis.
3. Results
3.1. Primary Microglia From Postnatal Day 0–4 C57BL/6 Mice Exhibited Differential Amoeboid Morphology When Exposed to Tmem119‐siRNA Alone or With OGD
Tmem119 is a transmembrane protein identified as a reliable marker for distinguishing microglia from macrophages (Bennett et al. 2016; Chunsheng Ruan et al. 2020; Satoh et al. 2019). Beyond serving as a microglia‐specific marker in the brain, emerging evidence suggests that Tmem119 may play a functional role in regulating microglial inflammatory signaling (Liu et al. 2025; Mercurio et al. 2022; Ruan and Elyaman 2022; Young et al. 2021). To investigate the inflammatory potential of microglial Tmem119, we manipulated microglial expression with Tmem119‐siRNA, with scrambled siRNA (Sc‐siRNA) as a control. The siRNA‐treated cells were subsequently subjected to oxygen–glucose deprivation (OGD), an in vitro model of ischemic injury (Figure 1). Primary microglia exhibited marked amoeboid morphology following siRNA treatment compared with untreated normoxic controls, and this effect was further exacerbated after OGD exposure (Figure 1A,B). These findings indicate that both siRNA transfection and ischemic stress modulate microglial morphology and activation. Importantly, the successful application of Tmem119‐siRNA in primary microglia provides an effective approach for investigating the functional role of Tmem119 in microglial responses to OGD‐induced injury.
FIGURE 1.

Tmem119‐siRNA promotes amoeboid microglial morphology. (A) Representative live images for male (upper panel) and female (lower panel) microglial morphology under normoxic conditions, scrambled siRNA (Sc‐siRNA), OGD only conditions, Sc‐siRNA + OGD (oxygen–glucose deprivation), Tmem119‐siRNA, and Tmem119‐siRNA + OGD treatments. Yellow arrows indicate ramified microglia, whereas white dashed circles indicate amoeboid microglia. (B) Quantification of amoeboid microglia expressed as the percentage of total microglial cells, across treatment groups. Data were analyzed using ordinary one‐way ANOVA followed by Tukey's multiple‐comparisons test. *p < 0.0001 is significant. n = 8 independent experiments. Microscopic fields were taken at 20× magnification. Sc‐siRNA is control.
3.2. Silencing Tmem119 in Primary Microglia Resulted in Elevated Expression of Proinflammatory Markers Following OGD and Subsequent Lipopolysaccharide (LPS) Stimulation
Neonatal (P0‐4) microglial Tmem119 protein levels were equivalent between male and female (Figure 2A–D; Supplementary Figure 2A,B for uncropped Western blots). Similarly, Tmem119 mRNA expression did not differ between control (normoxia) and OGD‐treated cells (Figure 2E), indicating that OGD alone does not affect microglial Tmem119 (Figure 2E). A cell viability assay measuring metabolically active cells showed no statistically significant difference in the number of viable cells between OGD‐treated and control groups (normoxia) (Supplementary Figure 8). Examining the effects of LPS stimulation alone on the expression of Tmem119, IRAK4, IRF5, and CD68 did not significantly alter the expression of these genes compared with untreated control microglia (Supplementary Figure 1), indicating that LPS alone was insufficient to induce measurable changes in these markers in our experimental system. We next treated microglia with Tmem119‐siRNA. Surprisingly, we observed that Tmem119 mRNA was significantly downregulated in male microglia but not in female microglia, suggesting female microglia are less responsive to Tmem119 siRNA at this treatment concentration, when compared to males (Figure 2F).
FIGURE 2.

Inflammatory mediator expression in primary microglia following Tmem119‐siRNA treatment. (A) Representative immunocytochemistry (ICC) images, and (B) quantification of Tmem119 expression in male (upper panel) and female (lower panel), primary microglia under resting (normoxic) conditions. (C) Western blot images showing Tmem119 and β‐actin expression, and (D) corresponding densitometric quantification of Tmem119/β‐actin ratios in resting microglia. (E) Tmem119 mRNA fold change in normoxic versus OGD‐microglia (combined male and female microglia). (F) Tmem119 mRNA fold change in male and female microglia treated with Sc‐siRNA, Tmem119‐siRNA or left untreated. (G‐J) mRNA fold change of Tmem119 (G), IRAK4 (H), IRF5 (I), and CD68 (J) following siRNA treatment and subsequent OGD plus lipopolysaccharide (OGD+LPS) stimulation. Statistical analysis was performed using ordinary two‐way ANOVA followed by Sidak's multiple‐comparisons test (F), or unpaired t tests. p < 0.05 is significant. Data are derived from n = 6 at 110 cells per microscopic field for ICC (A, B), n = 4 independent experiments (at 1 × 10⁶ cells per experiment) for Western blotting (C, D), and n = 6‐12 independent experiments (4 × 10⁵ cells per experiment) for gene expression analyses. (F) were 6 independent experiments pooled in pairs. G‐J, also represents independent experiments obtained from combined male and female microglia.
Inflammatory mediator expression and release are low in primary microglia, whereas LPS plus OGD stimulation robustly induces microglial responses (Al Mamun et al. 2020; Ngwa, Mamun, et al. 2021; Qi et al. 2021; Skrzypczak‐Wiercioch and Sałat 2022; Ye et al. 2020). To determine the effect of Tmem119 silencing on post‐ischemia inflammation, we subjected Tmem119‐siRNA‐treated microglia to OGD followed by LPS stimulation (100 ng/mL). siRNA treatment significantly reduced Tmem119 mRNA levels (Figures 2G), and this reduction markedly enhanced the expression of IRAK4, interferon regulatory factor 5 (IRF5), and CD68 mRNA (Figure 2H–J) but not IL‐1β, CD206, and IL‐10 (Supplementary Figure 2C–E). These findings indicate that loss of Tmem119 transcript sensitizes microglia to specific inflammatory activation following OGD and LPS challenge.
3.3. Reduction in Microglial Tmem119 Expression Led to Increased IRAK4
IRAK4 is a key downstream effector of Toll‐like receptor 4 (TLR4) and plays an important role in regulating innate immune responses by mediating the TLR4 signaling cascade (Bothe et al. 2024; De Nardo et al. 2018; Ngwa, Mamun, et al. 2021; Suzuki et al. 2002). We examined Tmem119 and IRAK4 protein expression in the brains of C57BL/6 male mice, 24 h after stroke with Western blotting (WB) (Figure 3). Following stroke, Tmem119 protein levels were significantly reduced in whole‐brain homogenates, whereas IRAK4 protein levels were increased (Figure 3A,A1,A2). To determine whether these changes were specific to microglia, we performed WB in cell lysates of microglia isolated from post‐stroke brain tissue using anti‐Tmem119‐PE antibody and anti‐PE nanobeads binding assay as in (Ngwa et al. 2025). We observed the similar oscillating pattern of Tmem119 downregulation and IRAK4 upregulation in microglia (Figure 3B,B1,B2) as in the whole brain (Figure 3A, Supplementary Figure 3 for uncropped Western blots). The data suggest that reduced Tmem119 expression is associated with increased IRAK4 expression following stroke.
FIGURE 3.

Differential expression of microglial Tmem119 and IRAK4 proteins during the hyperacute phase of ischemic stroke. (A–A2) Western blot images (A) showing Tmem119, IRAK4, and β‐Actin expression, with corresponding densitometric quantification of Tmem119/β‐Actin (A1) and IRAK4/β‐Actin (A2) ratios, in whole brain homogenates from stroke and sham control mice. (B–B2) Western blot images (B) showing Tmem119, IRAK4, and β‐Actin expression, with corresponding densitometric quantification of Tmem119/β‐Actin (B1) and IRAK4/β‐Actin (B2) ratios, obtained from microglial sorted using anti‐PE Nanobead‐antibody binding assay (MojoSort). Statistical analysis was performed using unpaired t‐tests. p < 0.05 significant. n = 6 male mice per group (3 used for whole brain homogenates and 3 for microglia‐only sorted homogenates).
3.4. Lenti‐Tmem119 Viral Delivery Was Well Tolerated in C57BL/6N Mice and Resulted in Robust Overexpression of Tmem119 in the Brain
To further examine the role of microglial Tmem119 in vivo after stroke, we used lentivirus to overexpress Tmem119 in microglia, in the brains of young C57BL/6N mice and then assessed Tmem119 protein and mRNA levels, 4 weeks after the viral injection/delivery (Figure 4). Lenti‐Tmem119 conjugated with promoter CX3CR1 specifically for microglia was stereotaxically injected into the mouse brain as previously reported (A. Al Mamun et al. 2020). IHC staining in brain slices showed significantly increased Tmem119 fluorescence intensity compared with those injected with lenti‐GFP control (Figure 4A,B; lower panel vs. upper panel). This increase was confirmed at the mRNA transcript level, with significant elevation in Tmem119 mRNA from microglia collected from the lenti‐Tmem119 vs. lenti‐GFP virus injected brains by MojoSort (Figure 4C). To evaluate the safety and tolerability of lentiviral administration, body weights were monitored for up to 47 days following saline, lenti‐GFP, or lenti‐Tmem119 injection, and no significant differences were observed among groups, indicating that viral delivery was well tolerated (Figure 4D). We next assessed the cellular specificity and anatomical distribution of transgene expression. Colocalization analyses demonstrated that more than 75% of Tmem119‐positive cells were also positive for GFP and Iba‐1, confirming efficient transduction of microglia by the lentiviral construct (Figure 4E,F). Representative whole‐brain images further demonstrated widespread GFP, Tmem119, and Iba1 expression throughout both hemispheres, including cortical and striatal regions, following the four‐site bilateral injection paradigm (Figure 4G). These findings indicate that lentiviral‐mediated Tmem119 overexpression was broadly distributed throughout the brain and was not restricted to the cortex. Collectively, these results demonstrate that lenti‐Tmem119 was efficiently delivered to and expressed in microglia, resulting in robust Tmem119 overexpression without detectable adverse effects across the animals included in this study.
FIGURE 4.

Validation of lentiviral Tmem119 expression in microglia. (A, B) Representative immunohistochemistry (IHC) images (A) and quantitative analysis (B) of Tmem119 expression in cortical brain sections from mice injected with lenti‐GFP (control) or lenti‐Tmem119 (Tmem119 expressing virus). For IHC quantification (B), Tmem119 fluorescence intensity was measured from three randomly selected microscopic fields per mouse in a blinded manner using images acquired at 20× magnification. (C) Tmem119 mRNA fold change in microglia isolated 4 weeks following lentiviral injection. For gene expression analysis (C), microglia were isolated using an anti‐PE Nanobead antibody‐binding assay (MojoSort). (D) Body weight measurements of mice injected with saline, lenti‐GFP, or lenti‐Tmem119, and then monitored for up to 47 days following treatment. (E) Representative images of lentiviral expression in the cortical region of mouse brain showing lenti‐GFP (left panels) and lenti‐Tmem119 (right panels). Merged images demonstrate colocalization of GFP or Iba‐1 with Tmem119. DAPI (blue) labels nuclei, GFP (green, left panels) or Iba‐1 (green, right panels) labels microglial markers, and Tmem119 is shown in red. Arrows (E) indicate GFP‐positive, Iba‐1‐positive, and Tmem119‐positive microglia, as well as microglia exhibiting colocalization of these markers with Tmem119 in merged images. (F) Quantitative analysis of the percentage colocalization of GFP or Iba‐1 with Tmem119 in microglia. Colocalization percentages were calculated as the ratio of GFP‐positive/Tmem119‐positive cells or Iba‐1‐positive/Tmem119‐positive cells. (G) Representative whole‐brain section showing infarcts and the distribution of GFP, Tmem119, and Iba‐1 expression following lentiviral transduction. Whole brain images were acquired at 10× magnification and on ischemic brain tissue. The area enclosed by the dashed circle in the brain slice (G) denotes the region of tissue injury identified in the CV, GFP or Tmem119 condition following stroke (first row slice stained with Crystal Violet, CV; last three rows of slices stained for GFP, Tmem119, Iba1, and merged images). Data are presented as mean ± SD, with n = 6 mice per group. Statistical analyses were performed using unpaired t‐tests or ordinary one‐way ANOVA followed by Tukey's multiple‐comparisons test, as appropriate. A value of p < 0.05 was considered statistically significant. Scale bar = 150 μm.
3.5. Enhancing Microglial Tmem119 Expression in Vivo Was Anti‐Inflammatory
Following stereotaxic injection of lenti‐Tmem119 into the brains of C57BL/6N male and female mice, animals were monitored for up to 56 days (including an additional observation period beyond 47 days), and no adverse effects were observed (Supplementary Figure 4). Microglia are the primary immune cells of the central nervous system and become rapidly activated following stroke injury (Patel et al. 2013; Zhang 2019). This activation shapes the post‐stroke immune milieu by releasing inflammatory mediators that exacerbate both local and systemic inflammation (Dong et al. 2021). To assess the effects of Tmem119 overexpression on post‐stroke inflammation, we quantified cytokine levels in the brain and plasma including IL‐1β, TNF‐α, IL‐4, and IL‐10 in mice treated with lenti‐Tmem119 vs. lenti‐GFP virus 3 days after MCAO (Figure 5). Among all cytokines measured, only IL‐10 levels in plasma and brain were significantly increased in the lenti‐Tmem119 treated mice compared with lenti‐GFP control (Figure 5A,B; Supplementary Figure 5A–F for the other cytokines). We next examined whether Tmem119 modulates IRAK4 signaling by assessing phosphorylated IRAK4 (p‐IRAK4) protein levels in brain homogenates using Western blot analysis (Figure 5C–E, Supplementary Figure 6 for uncropped Western blots). Tmem119 overexpression significantly reduced IRAK4 levels in the ischemic brain (Figure 5C,E) and increased Tmem119 protein expression (Figure 5C,D). Together, these findings suggest that Tmem119 overexpression selectively elevates IL‐10 levels during the acute post‐stroke period, likely through enhanced inhibition of downstream IRAK4 signaling in microglia.
FIGURE 5.

Cytokine and protein levels after ischemic injury in lenti‐Tmem119‐overexpressing mice. (A, B) anti‐inflammatory IL‐10 levels measured in plasma (A) from combined male and female mice and brain homogenates (B) from male mice, treated with lenti‐Tmem119 and lenti‐GFP. (C–E) Western blot images (C) showing Tmem119, p‐IRAK4, and β‐Actin expression, and with corresponding densitometric quantification of Tmem119/β‐Actin (D) and pIRAK4/β‐Actin (E) ratios, obtained from brain homogenates of lenti‐Tmem119 and lenti‐GFP male mice at 3 days post‐stroke. Statistical analysis was performed using unpaired t‐tests. p < 0.05 significant. n = 4 per group for brain cytokines and Western blot (male mice only, n = 8 independent brain homogenates pooled in pairs). n = 8–12 per group for plasma ELISA.
3.6. Microglial Tmem119 Is Protective After Stroke in Males
Manipulation of Tmem119 expression has led to changes of inflammatory mediators in mice (Figures 2 and 5). We next examined whether increasing Tmem119 expression using a lenti‐Tmem119 virus would impact stroke outcomes. Viruses were stereotaxically injected into WT mice brains, and 2 months later the mice were subjected to a 60 min MCAO. Three days after MCAO, a battery of behavioral tests and infarct volumes were assessed in both male and female mice (Figure 6). In male mice, lenti‐Tmem119 treatment resulted in a significantly smaller infarct in the ipsilateral hemisphere compared with the lenti‐GFP group (Figure 6A,B). In contrast, Tmem119 overexpression did not lead to infarct reduction in females (Figure 6C,D). Overexpression of Tmem119 did not affect total distance traveled (open field test) or grip strength relative to GFP controls (Figure 6E,F). However, lenti‐Tmem119 significantly improved alternation behavior (Y maze) and neurological deficit scores (NDS) compared with lenti‐GFP, but only in male mice (Figure 6G,H). Together, these data suggest that microglial Tmem119 protects young male mice but confers no neuroprotection in young female mice after stroke injury.
FIGURE 6.

Stroke outcomes in lenti‐GFP and lenti‐Tmem119‐expressing mice after 3‐day stroke. (A, C) Representative Cresyl violet‐stained brain sections from male (A) and female (C) mice injected with lenti‐GFP or lenti‐Tmem119. (B, D) Quantification of infarct volumes in the cortex, striatum and hemisphere from male (B) and female (D) mice. (E) distance traveled in open field test. (F) grip strength assessment. (G) Alternation test. (H) neurological deficits scores. Statistical analysis was performed using ordinary one‐way ANOVA with Tukey's multiple comparisons test or ordinary two‐way ANOVA followed by Sidak's multiple‐comparisons test. p < 0.05 is significant. n = 6–8 per group.
4. Discussion
In this study, we tested our hypothesis that Tmem119 functions as an anti‐inflammatory mediator by inhibiting IRAK4 signaling, thereby quenching post‐stroke inflammation to confer neuroprotection. To investigate this, we have performed both loss‐of‐function (in vitro) and gain‐of‐function (in vivo) assays to manipulate microglial Tmem119 expression and examined the effects of Tmem119 on stroke. Our Tmem119 silencing with siRNA (in vitro) or overexpression with lenti‐Tmem119 viral gene delivery (in vivo) was well tolerated and produced robust overexpression of Tmem119 in the brain, with no developmental abnormalities or post‐injection mortality. Using these approaches, we identified several key findings. Firstly, our findings demonstrate a see‐saw effect between Tmem119 and IRAK4 expression, in both the in vitro and in vivo data (Figures 2G,H, 3, and 5). Secondly, loss of Tmem119 mRNA expression in primary microglia led to increased expression of pro‐inflammatory mediators (IRF5 and CD68) following OGD + LPS stimulation (Figure 2I,J), suggesting that Tmem119 normally restrains inflammatory activation. Consistent with this, the gain of microglial Tmem119 before stroke enhanced anti‐inflammatory responses. Thirdly, sex differences were found in the response of Tmem119 signaling to manipulation. Male primary microglial Tmem119 expression is sensitive to siRNA, whereas female microglia were not responsive. Lentivirus injection of Tmem119 only improved stroke outcomes in male compared with female mice. To our knowledge, this is the first study to demonstrate a distinct and functionally significant role for microglial Tmem119 signaling in the context of stroke.
Microglia serve as the brain's primary immune sentinels, continuously surveying their environment for potential threats and rapidly altering their morphology and function in response to injury or infection to maintain neural homeostasis or trigger inflammation (Umpierre and Wu 2021; Young and Samuel 2025). Microglial homeostasis is maintained by transmembrane proteins, including Tmem119 (Butovsky and Weiner 2018; Liu et al. 2025). It has been found that Tmem119 expression was increased in the whole population of microglia paralleled with nervous tissue inflammation (Ruan and Elyaman 2022), probably due to an intrinsic Tmem119 response trying to maintain the brain homeostasis. However, at the hyperacute phase of stroke, we observed a reduction in Tmem119 expression on microglia (Figure 3). This may be reflective of the acute injury that causes microglia death in large numbers. Unlike other acute pathological events, microglial response to ischemic injury peaks at 2–3 days and persist for several weeks post‐stroke (Lalancette‐Hébert et al. 2007; Lee et al. 2014; Thomas 1992), initiating and perpetuating an immune response that potentially provides a broader therapeutic window in which intervention may improve outcome.
Following stroke, cytokine‐producing transcription factors in microglia such as NF‐κB (nuclear factor kappa‐light‐chain‐enhancer of activated B cells) and AP‐1 (activator protein‐1), are activated. This activation occurs through TLR4‐dependent assembly of the cytosolic Myddosome, composed of MyD88 and IRAK4 (Cushing et al. 2017; Ngwa, Mamun, et al. 2021). We have previously reported that microglial IRAK4 also phosphorylates interferon regulatory factor 5 (IRF5) and IRF4, and in turn mediates production of inflammatory cytokines (Ngwa, Mamun, et al. 2021). Our data (Figure 2I) demonstrated: (1) IRAK4 is inversely associated with Tmem119 signaling (Figures 2G,H and 3); and (2) IRF5 was also subjected to Tmem119 manipulation. Under physiological conditions, Tmem119 modulation is associated with altered IRAK4 signaling, thereby preventing IRF5 phosphorylation and its nuclear translocation (Figure 7A). However, (i) siRNA‐mediated silencing of Tmem119 followed by OGD with LPS stimulation (Figure 2G), or (ii) MCAO (Figure 3); disrupts the Tmem119‐IRAK4 association. This disruption results in enhanced IRAK4 activation and subsequent IRF5 phosphorylation. Phosphorylated IRF5 (pIRF5) then translocates to the nucleus, where it binds p‐TFREs (phosphor‐transcription factor response elements) to drive pro‐inflammatory gene expression (Figure 7B). Importantly, LPS stimulation alone did not significantly alter Tmem119, IRAK4, IRF5, or CD68 transcript expression under our experimental conditions (Supplementary Figure 1). These findings indicate that LPS alone is insufficient to induce the inflammatory changes observed following Tmem119 silencing and suggest that enhanced inflammatory signaling requires both reduced Tmem119 expression and OGD/LPS‐induced cellular stress. The lack of significant changes in Tmem119 mRNA expression following OGD alone (Figure 2E) suggests that the OGD model provides a reductionist system for assessing the direct effects of ischemia‐like conditions on microglia, independent of signals arising from other cell types and the broader tissue injury response that occurs in vivo following MCAO. Nevertheless, the absence of a corresponding change at mRNA level does not necessarily contradict with previous reports of reduced Tmem119 protein levels following stroke. mRNA and protein abundances can be uncoupled through translational and posttranslational regulatory mechanisms that alter protein synthesis, stability, and degradation. Moreso, Tmem119 expression is dynamically regulated in activated microglia under pathological conditions (Buccitelli and Selbach 2020; Franks et al. 2017; Ruan and Elyaman 2022). The absence of a significant Tmem119 transcript response to LPS alone (Supplementary Figure 1), however differs from previous reports. For example, intraperitoneal LPS administration reduced Tmem119 expression in a subset of microglia in Tmem119‐eGFP mice (Ma et al. 2024). This discrepancy may reflect differences between in vivo and in vitro experimental systems, including LPS exposure paradigms, the use of primary microglia cultures, and the absence of multicellular neuroimmune interactions in vitro (He et al. 2021; Koga et al. 2025; Ma et al. 2024). Collectively, these findings suggest that Tmem119 may influence microglial responses to ischemia and inflammatory stress by limiting activation of the IRAK4‐IRF5 signaling axis, without requiring substantial changes in Tmem119 transcript abundance.
FIGURE 7.

Mechanistic diagram of microglial Tmem119/IRAK4 inhibitory axis. Following stimulation by damage‐associated molecular patterns (DAMPs) after stroke, the Tmem119‐IRAK4 complex becomes destabilized, preventing the formation of a stable Myddosome in the cytoplasm (7A) and leading to IRAK4 phosphorylation. The phosphorylated IRAK4 (p‐IRAK4) promotes phosphorylation of the transcription factor interferon regulatory factor 5 (IRF5). Activated or phosphorylated IRF5 translocates to the nucleus, where it binds to phospho‐transcription factor regulatory elements (pTFREs), triggering the release of downstream inflammatory mediators (7B). Overexpression of lenti‐Tmem119 prior to stroke may restore the balance of Tmem119‐IRAK4 signaling, thereby reducing neuroinflammation and improving stroke outcomes, especially in male mice.
IRF5 (interferon regulatory factor 5) is a well‐established pro‐inflammatory transcription factor that mediates microglial production of inflammatory cytokine by exerting an opposing effect on the anti‐inflammatory interferon regulatory factor 4 (IRF4) (Al Mamun et al. 2020; Ngwa, Mamun, et al. 2021; Ngwa et al. 2025). The observed effects of Tmem119 silencing on IRAK4, IRF5, and CD68 transcription are consistent with enhanced microglial pro‐inflammatory responses and worsened stroke outcomes (Figure 6). However, the suppressive effect of Tmem119 on IRAK4 appears to be independent of classical pro‐inflammatory cytokine production, as no significant changes were observed in IL‐1β or TNF‐α, the pro‐inflammatory cytokines examined in this study (Supplementary Figure 5). The lack of changes in IL‐1β or TNF‐α suggests that Tmem119‐mediated modulation of IRAK4 does not primarily affect its kinase‐dependent pro‐inflammatory signaling. Given that IRAK4 also has scaffold‐dependent functions involved in non‐canonical signaling pathways (De Nardo et al. 2018; Vick and Starczynowski 2025), it is possible that Tmem119 preferentially influences these non‐inflammatory roles. However, further mechanistic studies are required to test this possibility. Notably, although statistical significance was not reached, we observed trends toward increased levels of several cytokines, including IL‐1β, TNF‐α, and IL‐4, in the Tmem119‐overexpressing groups (Supplementary Figure 5D–F). Because Tmem119 overexpression was restricted to microglia whereas cytokine measurements were performed using whole‐brain homogenates, the measured cytokine levels reflect the combined contributions of multiple cell types, including microglia, astrocytes, endothelial cells, infiltrating peripheral immune cells, and other resident brain cells. Consequently, alterations in microglial Tmem119 expression may not be directly reflected by proportional changes in total brain cytokine concentrations. Furthermore, increasing evidence suggests that post‐stroke glial responses are highly heterogeneous and may involve the concurrent expression of both pro‐inflammatory and anti‐inflammatory mediators. Therefore, these non‐significant trends should be interpreted cautiously. Direct cell‐specific analyses will be required to determine whether Tmem119 overexpression influences cytokine production in microglia and to define the mechanisms underlying these observations.
We have observed sex differences in the effects of microglial Tmem119 manipulation (Figures 2 and 6). Females were more resistant to Tmem119 manipulation by siRNA, and lenti‐Tmem119 treatment only changed stroke outcomes in males but not in females. These sex differences were not related to the Tmem119 expression levels per se, as microglial Tmem119 expression was equivalent in male and female microglia (Figure 2A,B). Instead, sexual dimorphism may be related to gonadal hormone's effects as we used young mice in this study. Estrogen (estradiol) promotes vasodilation during stroke by increasing cerebral blood flow, reducing vascular resistance, and improving reperfusion in ischemic tissue (Hurn and Macrae 2000; McCullough et al. 2001). It is possible that Estrogen's neuroprotection has reached the “ceiling effect” so much so that Tmem119 overexpression in microglia fails to confer further protective effects in females. Sex chromosomal effects may also play a role in the sex difference, as siRNA treatment was applied to primary microglia derived from P0‐4 mouse pups, an age when hormonal effects are minimal. These findings underscore the importance of considering biological sex in neuroscience research and therapeutic development. Furthermore, they suggest that divergent molecular pathways may govern microglial function in males and females, and that Tmem119‐targeted therapies may be effective in males but not in females, at least under the conditions examined.
All experiments were designed to selectively manipulate microglial Tmem119, as an important regulator of the inflammatory response, without altering the entire immune system. To achieve microglia‐targeted expression, we used Fractalkine receptor (CX3CR1) promoter, which is expressed almost exclusively in microglia in the brain (Camacho‐Hernández and Peña‐Ortega 2023; Wolf et al. 2013). The CX3CR1 promoter was conjugated to either Tmem119 or green fluorescent protein (GFP) to drive Tmem119 overexpression or to visualize microglia, respectively.
Cell specific therapy has been very promising due to the rapid development of lentiviral vectors and siRNA techniques (Clarke and McMillan 2014; Milone and O'Doherty 2018) and represents a therapeutic avenue due to their ability to more precisely target cell‐specific signaling pathways, avoiding wholesale suppression of inflammatory responses. Based on our results, pharmacological reagents could be potentially developed to modulate Tmem119 expression in microglia after stroke so that the pro‐inflammatory response can be reduced and the anti‐inflammatory response increased early after stroke to clear the ischemic debris and boost the tissue repair.
There are several limitations in our study that should be considered when interpreting these findings. One limitation is the use of the CX3CR1 promoter to overexpress Tmem119 in microglia, as CX3CR1 expression has also been detected in neurons and astrocytes at a low level (Meucci et al. 2000; Zhan et al. 2024). However, we employed multiple complementary approaches, including in vitro siRNA‐mediated knockdown and in vivo lentiviral manipulation, and these independent methods produced consistent results that strongly support our central hypothesis. Another limitation is that our analyses of the anti‐inflammatory roles of Tmem119 were restricted to the acute phase following stroke (3 days post‐MCAO). We selected this time point because infarction is largely mature by this stage (Figure 6A,C) (Al Mamun et al. 2020; Liu et al. 2009), and because microglial activation is at peak level (Al Mamun et al. 2020; Al Mamun et al. 2018; Lalancette‐Hébert et al. 2007; Lee et al. 2014; Liu et al. 2009; Thomas 1992), enabling investigation of the role of Tmem119 during this critical inflammatory phase. The inflammatory effects of Tmem119 during the chronic phase of stroke (e.g., 14–28 days post‐injury) and bilateral analyses of the ischemic brain (ipsilateral vs. contralateral) remain unknown. Future studies are therefore warranted to elucidate the bilateral and long‐term functional consequences of Tmem119 modulation and to characterize cellular dynamics during later stages of recovery. Third, our knockdown efficiency was assessed only at the Tmem119 mRNA level. Although siRNA treatment significantly reduced Tmem119 transcript expression, we were unable to reliably quantify Tmem119 protein levels in primary microglial cultures because of limited sample availability and technical challenges associated with protein detection. Consequently, we cannot directly confirm the extent of Tmem119 protein depletion following siRNA treatment. Future studies incorporating protein‐level analyses will be important to establish the relationship between Tmem119 abundance and the inflammatory phenotype observed after Tmem119 knockdown. Fourth, our findings suggest that optimization of Tmem119‐siRNA delivery may be required for male and female microglia. The observed sex‐dependent differences in knockdown efficiency may reflect differences in siRNA uptake, target engagement, or downstream regulatory mechanisms. Further investigation of these factors may improve the efficacy and interpretation of Tmem119‐targeted interventions across sexes. Finally, although Lenti‐GFP served as the primary control for the lentiviral overexpression experiments, we did not directly assess potential vector‐ or injection‐related inflammatory responses by measuring markers such as CD68, IL‐1β, and TNF‐α in saline‐ and Lenti‐GFP‐treated animals. Future studies incorporating these analyses will further strengthen the interpretation of Tmem119‐mediated effects in vivo.
In conclusion, our findings identify microglial Tmem119 signaling as an important regulator of post‐stroke neuroinflammation. Tmem119 overexpression was associated with reduced IRAK4 signaling, increased plasma and brain IL‐10 levels, and improved post‐stroke outcomes in male mice. Conversely, Tmem119 knockdown enhanced proinflammatory signaling in microglia. Collectively, these findings suggest that Tmem119 expression in microglia contributes to the regulation of neuroinflammatory responses and promotes recovery following ischemic stroke in male mice.
Author Contributions
A.F. conducting experiments, acquisition of data, analysis, and interpretation of data, and manuscript writing. C.N. project conception and design, conducting experiments, acquisition of data, analysis, and interpretation of data, and manuscript writing. Y.X. mouse breeding and colony maintenance. J.W. mouse breeding and colony maintenance. E.A.T., L.D.M., and F.L. contributed to conception and design, interpretation of data, and manuscript writing. All authors have read and approved the final version of the manuscript.
Funding
This work was supported by funding from AHA Grants 23POST1019058/25CDA1446193 to Conelius Ngwa, NIH Grant R01NS137633 to Eric A. Tanifum, and NIH Grants R01NS108779/R01NS129977 to Fudong Liu.
Ethics Statement
All studies were conducted in accordance with NIH guidelines for the care and use of laboratory animals and approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Texas Health Science Center at Houston McGovern Medical School.
Conflicts of Interest
The authors declare no competing interests, except Eric A. Tanifum. Eric A. Tanifum is a Consultant and holds company stock at Flavocure Biotech, INC.
Supporting information
Supplementary Figure 1. Gene expression in primary microglia following LPS stimulation. (A–D) mRNA fold change of Tmem119 (A), IRAK4 (B), IRF5 (C), and CD68 (D). Statistical analysis was performed using unpaired t‐tests. p < 0.05 is significant. Data are derived from n = 6 independent experiments and at 4 × 105 cells per experiment, for gene expression analyses.
Supplementary Figure 2. Uncropped Western blots (A, B) showing microglial Tmem119 and β‐actin protein levels in normal (resting) microglia. Inflammatory mediator mRNA fold changes (C–E) were measured in microglia transfected with scrambled siRNA or Tmem119‐siRNA, subjected to oxygen–glucose deprivation (OGD), and subsequently stimulated with lipopolysaccharide (LPS). Data represent n = 4 mice per group for Western blotting or 12 independent experiments for mRNA expression.
Supplementary Figure 3. Whole Western blots of microglial Tmem119, IRAK4, and β‐actin proteins during the hyperacute phase of ischemic stroke. (A) Uncropped Western blots of whole‐brain homogenates from sham‐operated and ischemic stroke mice probed for Tmem119, IRAK4, and β‐actin. (B) Uncropped Western blots of microglial‐only homogenates, isolated from sham and ischemic stroke mice using anti‐PE Nanobead antibody binding assay (Mojo Sort), and then assayed for Tmem119, IRAK4, and β‐actin. n = 3 male mice per group for whole brain and 6 mice pooled in 3 pairs for sorted microglia.
Supplementary Figure 4. Body weight measurements. Mice injected with lenti‐GFP or lenti‐Tmem119 virus was monitored for up to 47 days (and an additional 9 days) post‐injection prior to middle cerebral artery occlusion (MCAO) surgery. n = 12–16 male and female mice per group (time‐point).
Supplementary Figure 5. Plasma and brain cytokine levels following ischemic injury in lenti‐Tmem119‐overexpressing mice. (A) IL‐1β, (B) TNF‐α, and (C) IL‐4 levels measured in plasma. (D) IL‐1β, (E) TNF‐α, and (F) IL‐4 levels measured in brain homogenates. Mice injected with lenti‐GFP (control) or lenti‐Tmem119 were analyzed at 3 days post‐stroke. n = 8–12 mice per group for plasma, and = 4 mice for brain cytokines.
Supplementary Figure 6. Uncropped Western blots of whole‐brain homogenates at 3 days post‐stroke, showing microglial Tmem119, phosphorylated IRAK4 (p‐IRAK4), and β‐actin protein levels. n = 4‐paired male mice per group.
Supplementary Figure 7. Experimental timeline for lentiviral administration and MCAO surgery. The timeline illustrates the sequence and duration of lentiviral administration, transgene expression, MCAO surgery, and subsequent data collection, analysis and conclusion.
Supplementary Figure 8. MTS/PMS microglial cell viability assay following oxygen–glucose deprivation/reoxygenation (OGD/R). Cell viability was determined based on a Tetrazolium (MTS) and Electron coupling reagent (PMS) absorbance and expressed as a percentage of the control group. Data are presented as mean ± SD from 3 independent experiments. Statistical significance was determined using t‐test. *p < 0.05 is significant.
Data Availability Statement
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.
References
- Ajoolabady, A. , Kim B., Abdulkhaliq A. A., et al. 2025. “Dual Role of Microglia in Neuroinflammation and Neurodegenerative Diseases.” Neurobiology of Disease 216: 107133. 10.1016/j.nbd.2025.107133. [DOI] [PubMed] [Google Scholar]
- Al Mamun, A. , Chauhan A., Qi S., et al. 2020. “Microglial IRF5‐IRF4 Regulatory Axis Regulates Neuroinflammation After Cerebral Ischemia and Impacts Stroke Outcomes.” Proceedings of the National Academy of Sciences of the United States of America 117, no. 3: 1742–1752. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Al Mamun, A. , Chauhan A., Yu H., Xu Y., Sharmeen R., and Liu F.. 2018. “Interferon Regulatory Factor 4/5 Signaling Impacts on Microglial Activation After Ischemic Stroke in Mice.” European Journal of Neuroscience 47, no. 2: 140–149. 10.1111/ejn.13778. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bennett, M. L. , Bennett F. C., Liddelow S. A., et al. 2016. “New Tools for Studying Microglia in the Mouse and Human CNS.” Proceedings of the National Academy of Sciences of the United States of America 113, no. 12: E1738–E1746. 10.1073/pnas.1525528113. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bertot, C. , Groc L., and Avignone E.. 2019. “Role of CX3CR1 Signaling on the Maturation of GABAergic Transmission and Neuronal Network Activity in the Neonate Hippocampus.” Neuroscience 406: 186–201. 10.1016/j.neuroscience.2019.03.006. [DOI] [PubMed] [Google Scholar]
- Bothe, U. , Günther J., Nubbemeyer R., et al. 2024. “Discovery of IRAK4 Inhibitors BAY1834845 (Zabedosertib) and BAY1830839.” Journal of Medicinal Chemistry 67, no. 2: 1225–1242. 10.1021/acs.jmedchem.3c01714. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Buccitelli, C. , and Selbach M.. 2020. “mRNAs, Proteins and the Emerging Principles of Gene Expression Control.” Nature Reviews. Genetics 21, no. 10: 630–644. 10.1038/s41576-020-0258-4. [DOI] [PubMed] [Google Scholar]
- Butovsky, O. , and Weiner H. L.. 2018. “Microglial Signatures and Their Role in Health and Disease.” Nature Reviews. Neuroscience 19, no. 10: 622–635. 10.1038/s41583-018-0057-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cabe, P. A. , Tilson H., Mitchell C. L., and Dennis R.. 1978. “A Simple Recording Grip Strength Device.” Pharmacology, Biochemistry and Behavior 8, no. 1: 101–102. 10.1016/0091-3057(78)90131-4. [DOI] [PubMed] [Google Scholar]
- Camacho‐Hernández, N. P. , and Peña‐Ortega F.. 2023. “Fractalkine/CX3CR1‐Dependent Modulation of Synaptic and Network Plasticity in Health and Disease.” Neural Plasticity 2023: 4637073. 10.1155/2023/4637073. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Clarke, D. T. , and McMillan N. A.. 2014. “Cell‐Specific Therapy on Target.” Nature Nanotechnology 9, no. 8: 568–569. [DOI] [PubMed] [Google Scholar]
- Cushing, L. , Winkler A., Jelinsky S. A., et al. 2017. “IRAK4 Kinase Activity Controls Toll‐Like Receptor‐Induced Inflammation Through the Transcription Factor IRF5 in Primary Human Monocytes.” Journal of Biological Chemistry 292, no. 45: 18689–18698. 10.1074/jbc.M117.796912. [DOI] [PMC free article] [PubMed] [Google Scholar]
- De Nardo, D. , Balka K. R., Cardona Gloria Y., Rao V. R., Latz E., and Masters S. L.. 2018. “Interleukin‐1 Receptor‐Associated Kinase 4 (IRAK4) Plays a Dual Role in Myddosome Formation and Toll‐Like Receptor Signaling.” Journal of Biological Chemistry 293, no. 39: 15195–15207. 10.1074/jbc.RA118.003314. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Dong, R. , Huang R., Wang J., Liu H., and Xu Z.. 2021. “Effects of Microglial Activation and Polarization on Brain Injury After Stroke.” Frontiers in Neurology 12: 620948. 10.3389/fneur.2021.620948. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Franks, A. , Airoldi E., and Slavov N.. 2017. “Post‐Transcriptional Regulation Across Human Tissues.” PLoS Computational Biology 13, no. 5: e1005535. 10.1371/journal.pcbi.1005535. [DOI] [PMC free article] [PubMed] [Google Scholar]
- He, Y. , Taylor N., Yao X., and Bhattacharya A.. 2021. “Mouse Primary Microglia Respond Differently to LPS and Poly(I:C) in Vitro.” Scientific Reports 11, no. 1: 10447. 10.1038/s41598-021-89777-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hsiao, K. K. , Borchelt D. R., Olson K., et al. 1995. “Age‐Related CNS Disorder and Early Death in Transgenic FVB/N Mice Overexpressing Alzheimer Amyloid Precursor Proteins.” Neuron 15, no. 5: 1203–1218. 10.1016/0896-6273(95)90107-8. [DOI] [PubMed] [Google Scholar]
- Hurn, P. D. , and Macrae I. M.. 2000. “Estrogen as a Neuroprotectant in Stroke.” Journal of Cerebral Blood Flow and Metabolism 20, no. 4: 631–652. 10.1097/00004647-200004000-00001. [DOI] [PubMed] [Google Scholar]
- Kiani Shabestari, S. , Morabito S., Danhash E. P., et al. 2022. “Absence of Microglia Promotes Diverse Pathologies and Early Lethality in Alzheimer's Disease Mice.” Cell Reports 39, no. 11: 110961. 10.1016/j.celrep.2022.110961. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Koga, M. , Nakashima H., Saito M., et al. 2025. “Microglia‐Dependent LPS Preconditioning Prevents Neuroinflammation‐Induced Behavioral Deficits in Male Mice.” bioRxiv: the preprint server for biology 2025: 681580. 10.1101/2025.10.10.681580. [DOI] [Google Scholar]
- Kraeuter, A. K. , Guest P. C., and Sarnyai Z.. 2019. “The Open Field Test for Measuring Locomotor Activity and Anxiety‐Like Behavior.” Methods in Molecular Biology 1916: 99–103. 10.1007/978-1-4939-8994-2_9. [DOI] [PubMed] [Google Scholar]
- Lalancette‐Hébert, M. , Gowing G., Simard A., Weng Y. C., and Kriz J.. 2007. “Selective Ablation of Proliferating Microglial Cells Exacerbates Ischemic Injury in the Brain.” Journal of Neuroscience 27, no. 10: 2596–2605. 10.1523/JNEUROSCI.5360-06.2007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lambertsen, K. L. , Finsen B., and Clausen B. H.. 2019. “Post‐Stroke Inflammation‐Target or Tool for Therapy?” Acta Neuropathologica 137, no. 5: 693–714. 10.1007/s00401-018-1930-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lee, Y. , Lee S. R., Choi S. S., Yeo H. G., Chang K. T., and Lee H. J.. 2014. “Therapeutically Targeting Neuroinflammation and Microglia After Acute Ischemic Stroke.” BioMed Research International 2014: 297241. 10.1155/2014/297241. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Li, Q. , Lan X., Han X., and Wang J.. 2018. “Expression of Tmem119/Sall1 and Ccr2/CD69 in FACS‐Sorted Microglia‐ and Monocyte/Macrophage‐Enriched Cell Populations After Intracerebral Hemorrhage.” Frontiers in Cellular Neuroscience 12: 520. 10.3389/fncel.2018.00520. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Li, X. , Blizzard K. K., Zeng Z., DeVries A. C., Hurn P. D., and McCullough L. D.. 2004. “Chronic Behavioral Testing After Focal Ischemia in the Mouse: Functional Recovery and the Effects of Gender.” Experimental Neurology 187, no. 1: 94–104. 10.1016/j.expneurol.2004.01.004. [DOI] [PubMed] [Google Scholar]
- Lin, C. H. , Chen M. C., Lin L. L., et al. 2021. “Gut Epithelial IL‐27 Confers Intestinal Immunity Through the Induction of Intraepithelial Lymphocytes.” Journal of Experimental Medicine 218, no. 11: e20210021. 10.1084/jem.20210021. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Liu, F. , Schafer D. P., and McCullough L. D.. 2009. “TTC, Fluoro‐Jade B and NeuN Staining Confirm Evolving Phases of Infarction Induced by Middle Cerebral Artery Occlusion.” Journal of Neuroscience Methods 179, no. 1: 1–8. 10.1016/j.jneumeth.2008.12.028. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Liu, J. , Wang Z., Liang W., et al. 2025. “Microglial TMEM119 Binds to Amyloid‐β to Promote Its Clearance in an Aβ‐Depositing Mouse Model of Alzheimer's Disease.” Immunity 58, no. 7: 1830–1846.e1837. 10.1016/j.immuni.2025.04.018. [DOI] [PubMed] [Google Scholar]
- Ma, K. , Sun L., Shen M., et al. 2022. “Functional Assessment of the Cell‐Autonomous Role of NADase CD38 in Regulating CD8+ T Cell Exhaustion.” IScience 25, no. 5: 104347. 10.1016/j.isci.2022.104347. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ma, W. , Oswald J., Rios Angulo A., and Chen Q.. 2024. “Tmem119 Expression Is Downregulated in a Subset of Brain Metastasis‐Associated Microglia.” BMC Neuroscience 25, no. 1: 6. 10.1186/s12868-024-00846-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- McCullough, L. D. , Alkayed N. J., Traystman R. J., Williams M. J., and Hurn P. D.. 2001. “Postischemic Estrogen Reduces Hypoperfusion and Secondary Ischemia After Experimental Stroke.” Stroke 32, no. 3: 796–802. 10.1161/01.str.32.3.796. [DOI] [PubMed] [Google Scholar]
- Mercurio, D. , Fumagalli S., Schafer M. K., et al. 2022. “Protein Expression of the Microglial Marker Tmem119 Decreases in Association With Morphological Changes and Location in a Mouse Model of Traumatic Brain Injury.” Frontiers in Cellular Neuroscience 16: 820127. 10.3389/fncel.2022.820127. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Meucci, O. , Fatatis A., Simen A. A., and Miller R. J.. 2000. “Expression of CX3CR1 Chemokine Receptors on Neurons and Their Role in Neuronal Survival.” Proceedings of the National Academy of Sciences of the United States of America 97, no. 14: 8075–8080. 10.1073/pnas.090017497. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Meyer, O. A. , Tilson H., Byrd W., and Riley M.. 1979. “A Method for the Routine Assessment of Fore‐and Hindlimb Grip Strength of Rats and Mice.” Neurobehavioral Toxicology 1, no. 3: 233–236. [PubMed] [Google Scholar]
- Milone, M. C. , and O'Doherty U.. 2018. “Clinical Use of Lentiviral Vectors.” Leukemia 32, no. 7: 1529–1541. 10.1038/s41375-018-0106-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ngwa, C. , Al Mamun A., Qi S., et al. 2024. “Central IRF4/5 Signaling Are Critical for Microglial Activation and Impact on Stroke Outcomes.” Translational Stroke Research 15, no. 4: 831–843. 10.1007/s12975-023-01172-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ngwa, C. , Al Mamun A., Qi S., Sharmeen R., Xu Y., and Liu F.. 2022. “Regulation of Microglial Activation in Stroke in Aged Mice: A Translational Study.” Aging (Albany NY) 14, no. 15: 6047–6065. 10.18632/aging.204216. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ngwa, C. , Mamun A. A., Xu Y., Sharmeen R., and Liu F.. 2021. “Phosphorylation of Microglial IRF5 and IRF4 by IRAK4 Regulates Inflammatory Responses to Ischemia.” Cells 10, no. 2: 276. 10.3390/cells10020276. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ngwa, C. , Misrani A., Manyam K. V., et al. 2025. “Escape of Kdm6a From X Chromosome Is Detrimental to Ischemic Brains via IRF5 Signaling.” Translational Stroke Research 16, no. 5: 1496–1508. 10.1007/s12975-024-01321-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ngwa, C. , Misrani A., Xu Y., Wang J., Ritzel R., and Liu F.. 2026. “Peripheral CD200R Signaling: A Critical Regulator of Post‐Stroke Inflammation in Aged Mice.” Brain Research Bulletin 234: 111686. 10.1016/j.brainresbull.2025.111686. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ngwa, C. , Qi S., Mamun A. A., Xu Y., Sharmeen R., and Liu F.. 2021. “Age and Sex Differences in Primary Microglia Culture: A Comparative Study.” Journal of Neuroscience Methods 364: 109359. 10.1016/j.jneumeth.2021.109359. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Patel, A. R. , Ritzel R., McCullough L. D., and Liu F.. 2013. “Microglia and Ischemic Stroke: A Double‐Edged Sword.” International Journal of Physiology, Pathophysiology and Pharmacology 5, no. 2: 73–90. [PMC free article] [PubMed] [Google Scholar]
- Paul, S. , and Candelario‐Jalil E.. 2021. “Emerging Neuroprotective Strategies for the Treatment of Ischemic Stroke: An Overview of Clinical and Preclinical Studies.” Experimental Neurology 335: 113518. 10.1016/j.expneurol.2020.113518. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pereira, M. , and Gazzinelli R. T.. 2023. “Regulation of Innate Immune Signaling by Irak Proteins.” Frontiers in Immunology 14: 1133354. 10.3389/fimmu.2023.1133354. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Prieur, E. A. K. , and Jadavji N. M.. 2019. “Assessing Spatial Working Memory Using the Spontaneous Alternation Y‐Maze Test in Aged Male Mice.” Bio‐Protocol 9, no. 3: e3162. 10.21769/BioProtoc.3162. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Qi, S. , Al Mamun A., Ngwa C., et al. 2021. “X Chromosome Escapee Genes Are Involved in Ischemic Sexual Dimorphism Through Epigenetic Modification of Inflammatory Signals.” Journal of Neuroinflammation 18, no. 1: 70. 10.1186/s12974-021-02120-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Qi, S. , Ngwa C., Al Mamun A., et al. 2023. “X, but Not Y, Chromosomal Complement Contributes to Stroke Sensitivity in Aged Animals.” Translational Stroke Research 14, no. 5: 776–789. 10.1007/s12975-022-01070-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rimmerman, N. , Schottlender N., Reshef R., Dan‐Goor N., and Yirmiya R.. 2017. “The Hippocampal Transcriptomic Signature of Stress Resilience in Mice With Microglial Fractalkine Receptor (CX3CR1) Deficiency.” Brain, Behavior, and Immunity 61: 184–196. 10.1016/j.bbi.2016.11.023. [DOI] [PubMed] [Google Scholar]
- Ruan, C. , and Elyaman W.. 2022. “A New Understanding of TMEM119 as a Marker of Microglia.” Frontiers in Cellular Neuroscience 16: 902372. 10.3389/fncel.2022.902372. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ruan, C. , Sun L., Kroshilina A., et al. 2020. “A Novel Tmem119‐tdTomato Reporter Mouse Model for Studying Microglia in the Central Nervous System.” Brain, Behavior, and Immunity 83: 180–191. [DOI] [PubMed] [Google Scholar]
- Satoh, J. , Kino Y., Asahina N., et al. 2016. “TMEM119 Marks a Subset of Microglia in the Human Brain.” Neuropathology 36, no. 1: 39–49. 10.1111/neup.12235. [DOI] [PubMed] [Google Scholar]
- Satoh, J.‐i. , Kino Y., Yanaizu M., Ishida T., and Saito Y.. 2019. “Microglia Express TMEM119 in the Brains of Nasu‐Hakola Disease.” Intractable & Rare Diseases Research 8, no. 4: 260–265. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Skrzypczak‐Wiercioch, A. , and Sałat K.. 2022. “Lipopolysaccharide‐Induced Model of Neuroinflammation: Mechanisms of Action, Research Application and Future Directions for Its Use.” Molecules 27, no. 17: 5481. 10.3390/molecules27175481. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Smith, J. P. , Hicks P. S., Ortiz L. R., Martinez M. J., and Mandler R. N.. 1995. “Quantitative Measurement of Muscle Strength in the Mouse.” Journal of Neuroscience Methods 62, no. 1–2: 15–19. 10.1016/0165-0270(95)00049-6. [DOI] [PubMed] [Google Scholar]
- Suzuki, N. , Suzuki S., Duncan G. S., et al. 2002. “Severe Impairment of Interleukin‐1 and Toll‐Like Receptor Signalling in Mice Lacking Irak‐4.” Nature 416, no. 6882: 750–756. 10.1038/nature736. [DOI] [PubMed] [Google Scholar]
- Tabor, N. , Ngwa C., Mitteaux J., et al. 2021. “Differential Responses of Neurons, Astrocytes, and Microglia to G‐Quadruplex Stabilization.” Aging (Albany NY) 13, no. 12: 15917–15941. 10.18632/aging.203222. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Tanifum, E. A. , Devkota L., Ngwa C., et al. 2018. “A Hyperfluorinated Hydrophilic Molecule for Aqueous (19)F MRI Contrast Media.” Contrast Media & Molecular Imaging 2018: 1693513. 10.1155/2018/1693513. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Thomas, W. E. 1992. “Brain Macrophages: Evaluation of Microglia and Their Functions.” Brain Research Reviews 17, no. 1: 61–74. 10.1016/0165-0173(92)90007-9. [DOI] [PubMed] [Google Scholar]
- Umpierre, A. D. , and Wu L. J.. 2021. “How Microglia Sense and Regulate Neuronal Activity.” Glia 69, no. 7: 1637–1653. 10.1002/glia.23961. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Vankriekelsvenne, E. , Chrzanowski U., Manzhula K., et al. 2022. “Transmembrane Protein 119 Is Neither a Specific nor a Reliable Marker for Microglia.” Glia 70, no. 6: 1170–1190. 10.1002/glia.24164. [DOI] [PubMed] [Google Scholar]
- Vick, E. J. , and Starczynowski D. T.. 2025. “Irak Signaling in Cancers: Mechanisms, Targeting, and Clinical Implications.” Expert Opinion on Investigational Drugs 34, no. 10: 775–792. 10.1080/13543784.2025.2573646. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wang, Y. , Leak R. K., and Cao G.. 2022. “Microglia‐Mediated Neuroinflammation and Neuroplasticity After Stroke.” Frontiers in Cellular Neuroscience 16: 980722. 10.3389/fncel.2022.980722. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wolf, Y. , Yona S., Kim K.‐W., and Jung S.. 2013. “Microglia, Seen From the CX3CR1 Angle.” Frontiers in Cellular Neuroscience 7: 26. 10.3389/fncel.2013.00026. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Yang, L. , Qian J., Yang B., He Q., Wang J., and Weng Q.. 2021. “Challenges and Improvements of Novel Therapies for Ischemic Stroke.” Frontiers in Pharmacology 12: 721156. 10.3389/fphar.2021.721156. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ye, X. , Zhu M., Che X., et al. 2020. “Lipopolysaccharide Induces Neuroinflammation in Microglia by Activating the MTOR Pathway and Downregulating Vps34 to Inhibit Autophagosome Formation.” Journal of Neuroinflammation 17, no. 1: 18. 10.1186/s12974-019-1644-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Young, C. E. , and Samuel M. A.. 2025. “Microglia Sensing of Peripheral Signals That Bridge the Brain and Body.” Molecular Neurodegeneration 20, no. 1: 114. 10.1186/s13024-025-00905-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Young, K. F. , Gardner R., Sariana V., et al. 2021. “Can Quantifying Morphology and TMEM119 Expression Distinguish Between Microglia and Infiltrating Macrophages After Ischemic Stroke and Reperfusion in Male and Female Mice?” Journal of Neuroinflammation 18, no. 1: 58. 10.1186/s12974-021-02105-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Zhan, L. , Qiu M., Zheng J., et al. 2024. “Fractalkine/CX3CR1 Axis Is Critical for Neuroprotection Induced by Hypoxic Postconditioning Against Cerebral Ischemic Injury.” Cell Communication and Signaling 22, no. 1: 457. 10.1186/s12964-024-01830-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Zhang, S. 2019. “Microglial Activation After Ischaemic Stroke.” Stroke and Vascular Neurology 4, no. 2: 71–74. 10.1136/svn-2018-000196. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Zhao, J. F. , Ren T., Li X. Y., Guo T. L., Liu C. H., and Wang X.. 2022. “Research Progress on the Role of Microglia Membrane Proteins or Receptors in Neuroinflammation and Degeneration.” Frontiers in Cellular Neuroscience 16: 831977. 10.3389/fncel.2022.831977. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Supplementary Figure 1. Gene expression in primary microglia following LPS stimulation. (A–D) mRNA fold change of Tmem119 (A), IRAK4 (B), IRF5 (C), and CD68 (D). Statistical analysis was performed using unpaired t‐tests. p < 0.05 is significant. Data are derived from n = 6 independent experiments and at 4 × 105 cells per experiment, for gene expression analyses.
Supplementary Figure 2. Uncropped Western blots (A, B) showing microglial Tmem119 and β‐actin protein levels in normal (resting) microglia. Inflammatory mediator mRNA fold changes (C–E) were measured in microglia transfected with scrambled siRNA or Tmem119‐siRNA, subjected to oxygen–glucose deprivation (OGD), and subsequently stimulated with lipopolysaccharide (LPS). Data represent n = 4 mice per group for Western blotting or 12 independent experiments for mRNA expression.
Supplementary Figure 3. Whole Western blots of microglial Tmem119, IRAK4, and β‐actin proteins during the hyperacute phase of ischemic stroke. (A) Uncropped Western blots of whole‐brain homogenates from sham‐operated and ischemic stroke mice probed for Tmem119, IRAK4, and β‐actin. (B) Uncropped Western blots of microglial‐only homogenates, isolated from sham and ischemic stroke mice using anti‐PE Nanobead antibody binding assay (Mojo Sort), and then assayed for Tmem119, IRAK4, and β‐actin. n = 3 male mice per group for whole brain and 6 mice pooled in 3 pairs for sorted microglia.
Supplementary Figure 4. Body weight measurements. Mice injected with lenti‐GFP or lenti‐Tmem119 virus was monitored for up to 47 days (and an additional 9 days) post‐injection prior to middle cerebral artery occlusion (MCAO) surgery. n = 12–16 male and female mice per group (time‐point).
Supplementary Figure 5. Plasma and brain cytokine levels following ischemic injury in lenti‐Tmem119‐overexpressing mice. (A) IL‐1β, (B) TNF‐α, and (C) IL‐4 levels measured in plasma. (D) IL‐1β, (E) TNF‐α, and (F) IL‐4 levels measured in brain homogenates. Mice injected with lenti‐GFP (control) or lenti‐Tmem119 were analyzed at 3 days post‐stroke. n = 8–12 mice per group for plasma, and = 4 mice for brain cytokines.
Supplementary Figure 6. Uncropped Western blots of whole‐brain homogenates at 3 days post‐stroke, showing microglial Tmem119, phosphorylated IRAK4 (p‐IRAK4), and β‐actin protein levels. n = 4‐paired male mice per group.
Supplementary Figure 7. Experimental timeline for lentiviral administration and MCAO surgery. The timeline illustrates the sequence and duration of lentiviral administration, transgene expression, MCAO surgery, and subsequent data collection, analysis and conclusion.
Supplementary Figure 8. MTS/PMS microglial cell viability assay following oxygen–glucose deprivation/reoxygenation (OGD/R). Cell viability was determined based on a Tetrazolium (MTS) and Electron coupling reagent (PMS) absorbance and expressed as a percentage of the control group. Data are presented as mean ± SD from 3 independent experiments. Statistical significance was determined using t‐test. *p < 0.05 is significant.
Data Availability Statement
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.
